Your opinion does not appear to be congruent with the consensus of practicing physicians. As you can see from the table in #msg-52408979, Kaletra and Reyataz are almost even in global sales at $1.4B and are miles ahead of the third-biggest PI, Prezista.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.